ABT
Abbott Laboratories
Abbott Laboratories historical holders
total: 14
Longleaf Partners Abbott Laboratories transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
Mason Hawkins has been an institutional investor in Abbott Laboratories (ABT) since 2026 Q2. According to 2026 Q2 report, Mason Hawkins holds 506,914 shares with a market value of roughly $46.00M representing 4.38% of their equity portfolio. The fund/company first acquired ABT in 2026 Q2, initially purchasing 506,914 shares.
Does Mason Hawkins still hold ABT?
Yes, Mason Hawkins continues to hold Abbott Laboratories (ABT). According to their 2026 Q2 report, they maintain a position of 506,914 shares valued at approximately $46.00M, representing 4.38% of their equity portfolio.
When did Mason Hawkins first invest in ABT?
Mason Hawkins first invested in Abbott Laboratories (ABT) in 2026 Q2 at the reported quarter-end price of $90.74 per share, acquiring 506,914 shares in their initial purchase.
What is Mason Hawkins's average cost basis for ABT?
Based on historical transaction data, Mason Hawkins's estimated cost basis for Abbott Laboratories (ABT) is approximately $90.74 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $90.74
ABT transactions history by Longleaf Partners
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
4.38%
|
506,914
|
$90.74
|
$45,997,376
|
new
|
+4.38%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.